Prospective and Non-randomized Registry of CardioCel 3D
← catalyst calendarSponsored by LeMaitre Vascular (industry) · LMAT — their whole pipeline →. With Factory CRO for Medical Devices B.V..
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
200estimated
Sites
6
Countries
Germany, Italy, Spain +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-08-28 | actual | When the study began enrolling |
| Primary completion | Nov 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2019-11-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Intracardiac and Septal Defects
- Valve and Anulus Repair
- Great Vessel Reconstruction
- Peripheral Vessel Reconstruction
- Suture Line Buttressing
Intervention
- Device: CardioCel implantation
Primary outcomes
what the primary-completion date above is the date OFIncidence of graft related reintervention
measured 30 days post procedure.
Incidence of patch related morbidity
measured 30 days post procedure
Permalink · LMAT's whole pipeline · Catalyst calendar · Every registered study · What changed